This merger also meant a change in the name of the current calendar, from being called “Vaccination” “People’s Lifetime Immunization Program”.
Nirsevimab is used to treat respiratory syncytial virus, which causes a common viral illness that usually causes mild, cold-like symptoms.but it may result in severe infection In the lower airways and lungs, especially bronchiolitis and pneumonia, especially in infants, but also in the elderly and people with chronic diseases.
he RSV It can affect people of all ages and is so common in young children that more than 90% of children are already infected by the age of 2, causing a high disease burden in childhood and an overload of aid in childhood. primary health care picture hospital care During the virus season.
Children under 6 months are more burdened
The greatest load is concentrated at under 6 monthsand in general respiratory syncytial virus infection They occur in the fall or winter, so this seasonality leads to the highest rates of hospitalization in those born in the fall and winter.
Currently, there is a new drug that provides passive immunity against RSV.its about Nisevumaba monoclonal antibody (a laboratory-produced molecule intended as a surrogate that can Alter or mimic the immune system’s attack) for the prevention of RSV lower respiratory disease under 12 months In his first season against VRS. It has a good safety and efficacy profile and a long half-life, so it provides protection for at least 5 months after administration.
For all this, in castile and leon The lifetime immunization schedule includes a single dose of nirsevimab administered to children born between 1 March 2023 and 31 March 2024 during the 2023-2024 campaign.
Although Redacción Médica may contain statements, data or notes from health authorities or professionals, the information contained in Redacción Médica was compiled and prepared by journalists. We recommend that readers consult a health professional with any health-related questions.